Recombinant Human IL-1RAP protein (His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0827

---

Validation Data Gallery

• 

  Purity of Recombinant Human IL-1RAP was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human IL-1RAP protein Ser21-Glu359 (Accession# Q9NPH3-1) with a His tag at the C-terminus.
• GeneID: 3556
• Accession: Q9NPH3-1
• PredictedSize: 39.9 kDa
• SDS-PAGE: 50-60 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

IL-1RAP (Interleukin-1 receptor accessory protein), also known as IL-1RAcP, IL-1R-3, or IL-1R3, is a member of the interleukin-1 receptor family. IL-1RAP is composed of an extracellular region containing three Ig-like C2 type domains, a transmembrane region, and a cytoplasmic region with a TIR (Toll-IL-1-receptor) domain. IL-1RAP functions as a co-receptor for IL-1, IL-33, IL-36. It plays an essential role in the signaling of the IL-1 family cytokines such as IL-1, IL-33, and IL-36, as well as tyrosine kinases FLT3 and c-Kit. IL-1RAP can also exist in a soluble form.

References:

1. S A Greenfeder, et al. (1995). J Biol Chem. 270(23):13757-65.
2. M Dale, et al. (1998). Genomics. 47(2):325-6.
3. Alissa A Chackerian, et al. (2007). J Immunol. 179(4):2551-5.
4. Ali Zarezadeh Mehrabadi, et al. (2022). Immunology. 166(1):38-46. 
5. Jame Frenay, et al. (2022). Int J Mol Sci. 23(23):14918.